Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Pinnacle Wealth Management Advisory Group LLC

Pinnacle Wealth Management Advisory Group LLC grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,569 shares of the medical equipment provider’s stock after buying an additional 90 shares during the quarter. Pinnacle Wealth Management Advisory Group LLC’s holdings in Intuitive Surgical were worth $529,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ISRG. WCM Investment Management LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter worth $575,536,000. International Assets Investment Management LLC raised its stake in Intuitive Surgical by 32,360.5% in the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd lifted its holdings in Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after purchasing an additional 677,455 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Intuitive Surgical during the 3rd quarter worth about $178,667,000. Finally, Quadrature Capital Ltd grew its holdings in shares of Intuitive Surgical by 466.2% during the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after buying an additional 280,480 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 2.1 %

NASDAQ:ISRG traded down $8.28 during trading hours on Wednesday, hitting $380.37. The stock had a trading volume of 1,107,969 shares, compared to its average volume of 1,601,620. The business has a 50 day simple moving average of $385.34 and a two-hundred day simple moving average of $351.97. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The company has a market cap of $134.92 billion, a PE ratio of 68.66, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.00 EPS. Research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Piper Sandler upped their target price on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. BTIG Research raised their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Citigroup upped their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Finally, Wells Fargo & Company lifted their target price on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a report on Friday, January 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Insider Buying and Selling

In other Intuitive Surgical news, Director Mark J. Rubash sold 1,709 shares of Intuitive Surgical stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $380.00, for a total transaction of $649,420.00. Following the sale, the director now directly owns 16,051 shares in the company, valued at approximately $6,099,380. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Myriam Curet sold 481 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $386.09, for a total value of $185,709.29. Following the completion of the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $115,054.82. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mark J. Rubash sold 1,709 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $380.00, for a total value of $649,420.00. Following the transaction, the director now directly owns 16,051 shares in the company, valued at approximately $6,099,380. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 147,927 shares of company stock worth $57,064,459. 0.80% of the stock is currently owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.